Neuraminidase inhibitors produce a small reduction in duration of seasonal influenza in children and reduce transmission in affected households, but effects on serious complications unclear

Evidence-Based Medicine

Volumn 15, Issue 1, 2010, Pages 20-21

  Jefferson, Tom ^a  

^a Cochrane Acute Respiratory Infections Group ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN; OSELTAMIVIR; PARACETAMOL; SIALIDASE INHIBITOR;

CHILDHOOD DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE DURATION; GASTROINTESTINAL DISEASE; HOUSEHOLD; HUMAN; INFLUENZA; NOTE; PANDEMIC; PERSONAL HYGIENE; PRESCRIPTION; SEASONAL INFLUENZA; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 77249133608     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm.15.1.20     Document Type: Note

References (4)

1. World Health Organization. Global agenda on infl uenza surveillance and control. Geneva: WHO 2009. http://www.who.int/csr/disease/infl uenza/csrinfl uenzaglobalagenda/en/print.html (accessed 11 January 2010).
2. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating infl uenza in healthy adults: systematic review and meta-analysis. BMJ 2009;339:b5106.
3. Cohen D. Complications: tracking down the data on oseltamivir. BMJ 2009;339:b5387.
4. Doshi P. Neuraminidase inhibitors - the story behind the Cochrane review. BMJ 2009;339:b5164.